Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cardiotoxicity: full-pipeline trial registry
6 of 14 indexed Cardiotoxicity trials are currently recruiting.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 6 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Cardiotoxicity: 14 US clinical trials tracked, 6 recruiting.
Cardiotoxicity is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Abramson Cancer Center at Penn Medicine, running 4 of these trials.
Enrollment posture brief
Registry condition cardiotoxicity
OPEN 6 | RECR 43% | LATE 2 | EARLY 2 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Cardiotoxicity lists 6 open slots (43% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cardiotoxicity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cardiotoxicity is recruiting below its size-band peers.
6 of 14 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cardiotoxicity research.
Abramson Cancer Center at Penn Medicine accounts for 4 of 14 trials (28.6%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Cardiotoxicity enrolment sits around 200 participants.
Median target enrolment is 200 among the 14 trials that report a genuine target (sentinel values excluded). 5 of those (35.7%) plan for fewer than 100 participants.
-
Cardiotoxicity research leans observational.
5 interventional and 9 observational studies make up this index (35.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Global Cardio Oncology Registry
The Cleveland Clinic
NCT05598879
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Peerbridge Health
NCT06699056
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
NCT03418961
The STOP-MED CTRCD Trial
University Health Network, Toronto
NCT06183437
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Hari Narayan
NCT04262830
A Study of Blood Pressure Control During Cancer Treatment
Memorial Sloan Kettering Cancer Center
NCT06023576
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Abramson Cancer Center at Penn Medicine
NCT04305613
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05078190
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT05096338
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
Memorial Sloan Kettering Cancer Center
NCT05036252
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
Dana-Farber Cancer Institute
NCT07442578
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Abramson Cancer Center at Penn Medicine
NCT04023110
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Connecticut Children's Medical Center
NCT04036032
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
University of Minnesota
NCT02798679
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cardiotoxicity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cardiotoxicity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cardiotoxicity page
14 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Cardiotoxicity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abramson Cancer Center at Penn Medicine sponsors the most Cardiotoxicity trials on record, review their full trial history before evaluating a specific study. See Abramson Cancer Center at Penn Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiotoxicity condition card totals 14 registered trials; most-linked intervention Social Determinants of Health; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.